Brian A. Whiteman

Array ( [id] => 15606571 [patent_doc_number] => 10584335 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-03-10 [patent_title] => Single-stranded RNAi agents containing an internal, non-nucleic acid spacer [patent_app_type] => utility [patent_app_number] => 15/809777 [patent_app_country] => US [patent_app_date] => 2017-11-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 11 [patent_no_of_words] => 34769 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15809777 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14897557 [patent_doc_number] => 20190292544 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-26 [patent_title] => ALLERGEN DETECTION AGENTS AND ASSAYS [patent_app_type] => utility [patent_app_number] => 16/347935 [patent_app_country] => US [patent_app_date] => 2017-11-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 47722 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16347935 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17192093 [patent_doc_number] => 11160823 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-11-02 [patent_title] => Therapeutic targets for facioscapulohumeral muscular dystrophy [patent_app_type] => utility [patent_app_number] => 16/347688 [patent_app_country] => US [patent_app_date] => 2017-11-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 37 [patent_no_of_words] => 20722 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 86 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16347688 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15144871 [patent_doc_number] => 20190350913 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-21 [patent_title] => INHIBITORS OF GANGLIOSIDES METABOLISM FOR THE TREATMENT OF MOTOR NEURON DISEASES [patent_app_type] => utility [patent_app_number] => 16/345695 [patent_app_country] => US [patent_app_date] => 2017-11-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28928 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16345695 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12707758 [patent_doc_number] => 20180127752 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-10 [patent_title] => THERAPEUTICS TARGETING IGFBP7 FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND METABOLIC DISEASES [patent_app_type] => utility [patent_app_number] => 15/803453 [patent_app_country] => US [patent_app_date] => 2017-11-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19535 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15803453 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17378345 [patent_doc_number] => 11236343 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-02-01 [patent_title] => Method for producing dextran polymer-based, amplified nucleic acid aptamer nanoconstruct selectively capturing target molecule [patent_app_type] => utility [patent_app_number] => 16/346251 [patent_app_country] => US [patent_app_date] => 2017-11-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 9 [patent_no_of_words] => 5672 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 140 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16346251 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12185746 [patent_doc_number] => 20180044680 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-15 [patent_title] => 'METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF KRAS BY ASYMMETRIC DOUBLE-STRANDED RNA' [patent_app_type] => utility [patent_app_number] => 15/800440 [patent_app_country] => US [patent_app_date] => 2017-11-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 31 [patent_no_of_words] => 79742 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15800440 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17112158 [patent_doc_number] => 20210292755 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-23 [patent_title] => NOVEL DOUBLE-STRANDED OLIGONUCLEOTIDES FOR THE TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 16/345610 [patent_app_country] => US [patent_app_date] => 2017-10-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11035 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16345610 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13902523 [patent_doc_number] => 20190040466 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-07 [patent_title] => MICRO-RNA PROFILING, COMPOSITIONS, AND METHODS OF TREATING DISEASES [patent_app_type] => utility [patent_app_number] => 15/791147 [patent_app_country] => US [patent_app_date] => 2017-10-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9981 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 70 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15791147 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12159178 [patent_doc_number] => 20180030445 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-01 [patent_title] => 'COMPOSITIONS AND METHODS USING CAPSIDS RESISTANT TO HYDROLASES' [patent_app_type] => utility [patent_app_number] => 15/786370 [patent_app_country] => US [patent_app_date] => 2017-10-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 28153 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15786370 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15039245 [patent_doc_number] => 20190330627 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-31 [patent_title] => INDUCER OF MUSCLE DIFFERENTIATION (AS AMENDED) [patent_app_type] => utility [patent_app_number] => 16/341291 [patent_app_country] => US [patent_app_date] => 2017-10-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11512 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16341291 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12585675 [patent_doc_number] => 20180087054 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-03-29 [patent_title] => ANGIOPOIETIN-LIKE 3 (ANGPTL3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 15/782091 [patent_app_country] => US [patent_app_date] => 2017-10-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40883 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 78 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15782091 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13444807 [patent_doc_number] => 20180273946 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-27 [patent_title] => MODULATION OF TRANSTHYRETIN EXPRESSION [patent_app_type] => utility [patent_app_number] => 15/729860 [patent_app_country] => US [patent_app_date] => 2017-10-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 53790 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15729860 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17923035 [patent_doc_number] => 11466270 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-10-11 [patent_title] => Means and methods to treat inflammatory diseases [patent_app_type] => utility [patent_app_number] => 16/332575 [patent_app_country] => US [patent_app_date] => 2017-10-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 12 [patent_no_of_words] => 14626 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16332575 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15491577 [patent_doc_number] => 20200045977 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-13 [patent_title] => METHODS OF PRESERVING THE BIOLOGICAL ACTIVITY OF RIBONUCLEIC ACIDS [patent_app_type] => utility [patent_app_number] => 16/339866 [patent_app_country] => US [patent_app_date] => 2017-09-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3026 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16339866 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14597331 [patent_doc_number] => 10351850 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-07-16 [patent_title] => Double-stranded ribonucleic acid as control against insects [patent_app_type] => utility [patent_app_number] => 15/709890 [patent_app_country] => US [patent_app_date] => 2017-09-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 8610 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 93 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15709890 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12607302 [patent_doc_number] => 20180094264 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-04-05 [patent_title] => AAV TREATMENT OF HUNTINGTON'S DISEASE [patent_app_type] => utility [patent_app_number] => 15/705909 [patent_app_country] => US [patent_app_date] => 2017-09-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27166 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15705909 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12125141 [patent_doc_number] => 20180008724 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-01-11 [patent_title] => 'MODIFIED RNAi AGENTS' [patent_app_type] => utility [patent_app_number] => 15/706389 [patent_app_country] => US [patent_app_date] => 2017-09-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35119 [patent_no_of_claims] => 36 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15706389 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12886072 [patent_doc_number] => 20180187199 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-05 [patent_title] => MULTI-TARGET MODULATION FOR TREATING FIBROSIS AND INFLAMMATORY CONDITIONS [patent_app_type] => utility [patent_app_number] => 15/701298 [patent_app_country] => US [patent_app_date] => 2017-09-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18471 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15701298 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14774957 [patent_doc_number] => 20190262376 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-29 [patent_title] => COMPOSITIONS COMPRISING ANTISENSE-ENCODED ERYTHROPOIETIN RECEPTOR AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/333046 [patent_app_country] => US [patent_app_date] => 2017-09-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18259 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16333046 [rel_patent_id] =>[rel_patent_doc_number] =>)